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Abstract
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide, mainly due to
its high rates of postoperative recurrence and metastasis. It currently ranks as the third most common cause of
cancer-related deaths. MiRNAs are a set of small, single-stranded, non-coding RNA molecules that negatively
regulate gene expression at the post-transcriptional level. In this study, we demonstrated the
down-regulation of miR-148a in HCC and non-cancerous tissues using qRT-PCR.
Methods: Ninety six HCC samples and their noncancerous normal liver tissues were collected. Total mRNA
including miRNA was extracted, and miR-148a expression was determined using qRT-PCR. Furthermore, the
correlation between the miR-148a expression and clinicopathological parameters was investigated.
Results: The result showed that reduction of miR-148a expression was associated with TNM stage, metastasis,
and number of tumor nodes. Multivariate Cox proportional hazards model analysis showed that low expression of
miR-148a was independently associated with recurrence of HCC in the current study. Moreover, our result showed
that lower expression in tumor tissues in comparison with corresponding normal control tissues.
Conclusion: Down-regulation of miR-148a is related to HCC carcinogenesis and deterioration of HCC. MicroRNA-148a
may act as a suppressor miRNA of HCC, and it is therefore a potential prognostic biomarker for HCC patients.
Background
Hepatocellular carcinoma (HCC) is known as the sixth
common malignancies all over the world, and is the sec-
ond cause of cancer-related mortality [1, 2]. In 2012,
782,000 new cases and 746,000 deaths from HCC have
been reported. Although the clinical staging have used
in clinical decision, but improvement of molecular mech-
anism can be useful to clarify the role of new markers in
the treatment and prognosis of HCC [3].
MicroRNAs (miRNAs) are a class of small non-coding
RNAs [4]. It has been reported that dysregulation of
miRNA expression profiles presented in HCC cancer
and indicated that miRNAs can be beneficial markers
for HCC progression and clinical course [5–9]. MiRNAs
are as either oncogenes or tumor suppressors in human
carcinogenesis [10]. The mature members of miR-148/
152 family have been proved to be expressed in different
tumors that paly significant role in development and
tumorigenesis.
In addition, down-regulation of MiRNA-148a, was
previously shown in many types of cancers [11, 12].
These studies suggested that MiRNA-148a has prognostic
value in clinical evaluations and can act as tumor-
suppressor miRNAs. In current study, we evaluated the
clinical significance of miR-148a in HCC patient and its
association with clinicopathological features.
Methods
Patients
This retrospective study, we investigated 96 patients
diagnosed with HCC who had undergone surgery at
Tehran hospitals between May 2008 to September 2013.
Moreover, adjacent noncancerous liver tissues were at
least 2 cm away from the tumor node, were obtained
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from 30 patients who underwent surgery for reasons
other than malignancy. Tissues were snap frozen in li-
quid nitrogen after surgical resection until use. The clin-
icopathological features of the patients are summarized
in Table 1. This study was approved by the Research
Ethics Committee. In addition, the diagnosis and the
histologic grade were confirmed by two pathologists.
RT-qPCR assay
Total RNA was purified using TRIzol® reagent (Invitro-
gen Life Technologies, Carlsbad, CA, USA). Moreover,
we applied a miRNA Reverse Transcription kit (Invitro-
gen Life Technologies) to convert RNA into cDNA.
RT-qPCR was carried out using a miRNA qPCR De-
tection kit (GeneCopoeia, Rockville, USA) by system of
thermocycler. We used the comparative cycle threshold
(CT) method to calculate changes in expression. The
relative amount of miR-148a was normalized with U6
gene as internal reference. In addition, the 2−ΔΔCt method
was used to evaluate the expression level of miR-148a in
cancer and normal samples were evaluated.
Statistical analysis
SPSS software 20.0 (Chicago, IL, USA) was used for stat-
istical analysis. The chi-square test was used to assess
miR-148a expression with respect to clinicopathological
factors. Kaplan-Meier Survival method was used to
evaluate the association between miR-148a and recur-
rence P < 0.05 was considered to indicate a statistically
significant difference.
Results
Significantly decreased expression of miR-148a was
observed in the HCC tissues than in the adjacent nor-
mal hepatic tissues. ROC analysis was used to evaluate
the diagnostic value of miR-148a. The area under the
curve (AUC) of miR-148a was 0.837 (95 % CI 0.782 -
0.954, P < 0.035). In addition, the median 2-Δcq 0.93 was
calculated as the cut-off value of miR-148a. As shown in
Fig. 1, the sensitivity and specificity were calculated to be
80 % and 62.2 %, respectively. Furthermore, results
suggested that expression of miR-148a in advanced stages
(III and IV) was remarkably low than that in early stages
(I and II), (P = 0.042). Low expression was also associated
with metastasis (P = 0.021). However, miR-148a expres-
sion was not associated with sex (P = 0.712), age (P =
0.462), Tumor diameter (P = 0.316), liver cirrhosis
(0.621), and differentiation (P = 0.412), (Table 1). The
result indicated that the patients with low expression of
miR-148a had a longer time-to-recurrence when
Table 1 Relationship between the miR-148a expression and
clinicopathological features of patients with HCC (X− ± S)
Characteristic Number miR-148a expression
2-Δcq T P value
Gender
Male 55 0.71 ± 0.40 0.561 0.712
Female 41 0.85 ± 0.58
Age
≤60 42 0.74 ± 0.71 −0.579 0.462
>60 54 0.95 ± 0.47
Tumor diameter (cm)
≤5 55 0.84 ± 0.43 3.734 0.316
>5 47 0.80 ± 0.58
Vein invasion
Negative 81 0.77 ± 0.43 −0.273 0.131
Positive 20 0.80 ± 0.55
With cirrhosis
Negative 18 0.71 ± 0.45 −0.236 0.621
Positive 78 0.80 ± 0.52
Metastasis
Yes 46 0.82 ± 0.46 −1.767 0.021
No 50 1.32 ± 0.63
TNM stage
I + II 41 1.53 ± 0.41 4.126 0.042
III + IV 55 0.86 ± 0.34
Differentiation
Well 4 0.71 ± 0.32 −0.842 0.412
Moderate 77 0.85 ± 0.47
Poor 15 0.62 ± 0.34
Fig. 1 The area under the curve (AUC) of miR-148a with the sensitivity
and specificity were calculated to be 80 % and 62.2 %, respectively









compared with low expression patients (1.47 ± 0.42;
2.87 ± 0.64 mean ± SD), Nevertheless, there was no sig-
nificant difference between two groups (P = 0.417).
Multivariate Cox proportional hazards model analysis
showed that low expression of miR-148a was independ-
ently associated with recurrence of HCC (HR = 2.68; 95 %
CI: 1.416-8.367, P = 0.026).
Discussion
This study aimed to evaluate the clinical significance of
miR-148a in HCC patient and its association with clini-
copathological features. Significantly decreased expres-
sion of miR-148a was observed in the HCC tissues than
in the adjacent normal hepatic tissues. This finding sug-
gested that miR-148a could play a key role in suppression
and progression of tumor. The ROC curve suggested a
moderate diagnostic value of miR-148a in HCC with the
AUC as 0.837. The results of our study, together with
those reported previously, suggested that miR-148a plays
a critical role as oncogene or tumor suppressor in many
tumors [11–14]. On the other hand, Zhao et al. reported
that up-regulation of miR-148b induced the apoptosis and
cell-cycle arrest of pancreatic cancer cells by targeting
AMPKa1 [13]. In addition, miR-148b was reported to
regulate the metastasis of hepatocellular carcinoma cells
through targeting CCK2R [13].
Concerning the relationship between expression of
miR-148a and clinicopathological features, the expres-
sion level of miR-148a in advanced stages (III and IV)
was remarkably low than that in early stages (I and II),
(P = 0.042). In addition, low expression was also associ-
ated with metastasis (P = 0.021). It has been previously
reported that miR-148b might be linked to tumor inva-
sion and progression in many kind of tumors, in the
present study, similar trend was observed [12, 15–20].
However, Cuk K et al. found that miR-148b is signifi-
cantly upregulated in the plasma of breast cancer pa-
tients and may be used for the efficient diagnosis [21].
Previously, miR-148b was suggested to be upregulated in
ovarian cancer, and its upregulation may be involved in
the early stage of ovarian carcinogenesis [22]. Recently,
Gailhouste et al. [23] showed that miR-148a could pro-
mote the hepatospecific phenotype, and acted as a tumor
suppressor by targeting the c-Met oncogene. It was found
that overexpression of miR-148a led to a notable inhib-
ition of the invasive properties of hepatocellular car-
cinoma cells, whereas silencing of miR-148a promoted
hepatocellular carcinoma cell invasion [23]. These con-
troversial results of miR-148a in cancer development
may reflect the diverse roles of miR-148a in different
types of cancer. In the present study, we identified that
miR-148a is a predominantly downregulated miRNA in
HCC tissues compared with normal liver tissues by
using qRT-PCR assay, suggesting that miR-148a might
be implicated in tumorigenesis. Mentioned studies and
this current study, point in the same direction, that
there is a remarkable association between miR-148a
and the infiltration of tumor cells, migration, invasion
and metastasis of tumors. Hence, it may be useful to
clinically evaluate miR-148a expression for the predic-
tion of metastasis and deterioration in HCC patients.
In the next step, we evaluate the association between
miR-148a and recurrence. The result suggested that the
patients with low expression of miR-148a had a longer
time-to-recurrence when compared with low expression
patients (1.47 ± 0.42; 2.87 ± 0.64 mean ± SD), Neverthe-
less, there was no significant difference between two
groups (P = 0.417). A larger cohort is required to evalu-
ate the relationship between miR-148a and tumor recur-
rence in future studies. The mechanisms whereby miR-
148a was down-regulated in the advanced stages of HCC
could be associated with diverse target genes and path-
ways involved. Therefore further investigation is needed
to clarify such mechanisms.
Multivariate Cox proportional hazards applied in the
present study which suggested that low expression of
miR-148a was independently associated with recurrence
of HCC (HR = 2.68; 95 % CI: 1.416-8.367, P = 0.026).
Conclusions
In conclusion, the findings indicated that down-regulation
of miR-148a is related to HCC carcinogenesis and deteri-
oration of HCC. MicroRNA-148a may act as a suppressor
miRNA of HCC, and it is therefore a potential prognostic
biomarker for HCC patients.
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